为了量产钪-44，杨文江团队创新靶制备工艺，自主开发纯化流程，历经700多个日夜，进行了50多 次全流程实验、上千次数据模拟、工艺优化。 优质医用同位素钪-44在鲁实现国内首次量产 为肿瘤精准诊疗新型PET显像剂，产业前景广阔 "99毫居里！"日前，在济南中科核技术研究院里，伴随着一阵欢呼，该院杨文江副研究员团队得到 了活度百毫居里量级、核纯度大于99%、放射化学纯度大于99%的放射性核素钪-44，在我国首次实现了 钪-44量产。此举缩小了与国外的差距，为肿瘤诊疗提供了一种分辨率更高、更方便制药的显像剂。 13日，记者在济南中科核技术研究院看到，隔着4米厚的墙，实验人员用回旋加速器"轰击"天然硝 酸钙靶。"质子把钙-44原子核的一个中子'撞'出来，就得到钪-44。"该院副研究员王一正告诉记者， 钪-44生产工艺复杂，此前国内只能做到实验室量级。而国外10年前便开始研发，已实现量产，进行了 药物研发与临床试验。 孙晓蓉介绍，当前临床最常用的放射性同位素是氟-18，将其标记到脱氧葡萄糖上，就得到了FDG （氟代脱氧葡萄糖）示踪剂，能敏锐地发现多种糖代谢旺盛的肿瘤。但氟-18半衰期仅110分钟，必须凌 晨生产、清晨 ...

Core Insights - The successful commissioning of the cyclotron at the medical isotope production base in Mianyang, Sichuan, marks a significant advancement in the autonomous production capacity of key medical isotopes such as Gallium-68, Copper-64, and Iodine-123 [1][2] Company Overview - China General Nuclear Power Corporation Isotope Company is a wholly-owned subsidiary of China General Nuclear Technology (000881), focusing on the research, production, sales, and service of nuclear medicines [2] - The company has developed a diversified product matrix of medical isotopes, addressing urgent clinical needs and cutting-edge research [2] Product Development - Gallium-68, produced through the company's self-developed Gallium generator, provides stable support for clinical applications despite its short half-life of 67.71 minutes [2] - Copper-64 offers new diagnostic methods for neuroendocrine tumors and Alzheimer's disease due to its superior imaging characteristics [2] - Zirconium-89 serves as a critical probe for antibody drug development, accelerating targeted therapy innovations [2] - Iodine-123 enhances diagnostic accuracy for thyroid and cardiac diseases with its low radiation and high imaging quality [2] Quality Management and Collaboration - The company adheres to Good Manufacturing Practice (GMP) standards, establishing a comprehensive quality management system covering facilities, processes, and quality control [3] - An open and shared research platform is available for universities, research institutions, and enterprises, promoting collaborative innovation in proton technology and new isotope development [3] Brand Development - The company launched its medical isotope brand "Hejia," symbolizing the commitment to improving human life through nuclear technology, alongside the registration of the "IsoNosis" trademark for its isotope products [3] Industry Impact - The autonomous development and stable supply of medical isotopes by the company significantly contribute to the collaborative growth of China's new medical isotope industry, enhancing the country's nuclear medicine sector [3] - The company aims to deepen cooperation with medical institutions and research units to improve diagnostic capabilities for major diseases and expedite the delivery of precision medical solutions to clinical settings [3]

Group 1: Economic Transformation of Leshan - Leshan, a city with a GDP of 253.3 billion, is making significant strides in the hardcore technology sector, moving beyond its traditional image of scenic landscapes and local cuisine [1][17] - The city has a rich industrial heritage, exemplified by the legacy of Hou Debang, who established a foundational chemical industry in China with his patented method [4][6] - The chemical company Fuhua Chemical has emerged as a leader in the agricultural chemical sector, ranking among the top 20 globally and producing significant quantities of glyphosate and sodium dihydrogen phosphate [6][7] Group 2: Innovations in New Energy - Fuhua Chemical is leveraging its expertise to enter the new energy market, particularly in lithium iron phosphate production, which is in high demand due to the growth of electric vehicles [7] - The company can produce approximately 20,000 tons of lithium iron phosphate annually from its waste materials, capturing nearly 10% of the market share by 2024 [7] - The chemical industry cluster in Wutongqiao is projected to generate a value of 32.4 billion by 2024, with multiple green chemical projects underway [7][8] Group 3: Strategic Industry Development - Sichuan Weili Energy Co., Ltd. has successfully entered the all-vanadium flow battery market, which offers advantages over lithium batteries, such as higher safety and longer lifespan [10][11] - The company has created a complete supply chain for vanadium-based energy storage, contributing to the local economy and attracting related businesses to Leshan [11][12] - The development of industries in Leshan is guided by a clear understanding of local resources and strengths, allowing for strategic positioning in emerging markets [12] Group 4: Cross-Industry Innovations - Jiajing County, known for its bamboo paper production, is diversifying into high-tech industries such as nuclear medicine and aerospace materials [13][14] - The establishment of a major medical isotope production facility has positioned Jiajing as a leader in nuclear medicine, breaking international monopolies [13] - The county is also developing a comprehensive ecosystem for drone technology, supported by local resources and infrastructure [16] Group 5: Government Support and Policy - Leshan's government is implementing a dual-driven strategy of industrial strength and cultural tourism, aiming to reshape the city's industrial landscape [17][19] - Initiatives include streamlined project services and tax incentives to support businesses in their transformation and growth [19] - The city's approach serves as a model for other regions, demonstrating that success in high-end industries is achievable through strategic resource management and industry alignment [19]

Investment Rating - The report recommends a "Buy" rating for the industry, predicting that the industry index will outperform the Shanghai Composite Index by 10% or more during the specified period [6]. Core Insights - The company sold 240,000 pounds of U₃O₈ in Q3 2025, with an average spot price of approximately $74.66 per pound, leading to total revenue of $17.71 million, a 338% year-over-year increase [2][22]. - The company expects to achieve an annual U₃O₈ production of approximately 1 million pounds in 2025, with Q4 production expected to contribute significantly to this target [9][10]. - The average realized price for U₃O₈ in Q3 2025 was $72.38 per pound, with a gross margin of 26% [3][22]. - The company has a total uranium inventory of 2.125 million pounds as of September 30, 2025, which includes 485,000 pounds of finished U₃O₈ [4]. - The company anticipates a significant increase in cash profits due to lower mining costs and expects gross margins to continue to grow through 2026 [5][13]. Summary by Sections Uranium Business - **Production**: In Q3 2025, the company mined approximately 465,000 pounds of uranium ore, with a total uranium content of about 1.245 million pounds U₃O₈ as of September 30, 2025 [1]. - **Sales**: The company sold 240,000 pounds of U₃O₈ in Q3 2025, with a total revenue of $17.71 million [2][22]. - **Pricing**: The weighted average realized price was $72.38 per pound, with a gross margin of 26% [3]. - **Inventory**: The total uranium inventory was 2.125 million pounds, with an increase due to production from various mines [4]. - **Cost**: The average cost of finished U₃O₈ inventory was approximately $53 per pound, reflecting the company's efforts to improve production efficiency [7]. - **Guidance**: The company expects to mine between 5.5 million to 8 million tons of ore in 2025, containing approximately 875,000 to 1,435,000 pounds of U₃O₈ [8]. Rare Earth Business - **Heavy Rare Earth**: The company successfully produced 99.9% pure dysprosium oxide, exceeding commercial specifications [15]. - **Price Trends**: The price of praseodymium-neodymium (NdPr) increased by approximately 25% from June 30, 2025, to September 30, 2025 [17]. - **Project Development**: The company is advancing the Donald project, which is expected to produce approximately 7,200 tons of rare earth oxides annually [18]. Financial Performance - **Revenue Growth**: The company reported total revenues of $17.71 million in Q3 2025, a significant increase compared to the previous year [22]. - **Net Loss**: The net loss for Q3 2025 was $16.7 million, an improvement from the previous quarter [22]. - **Liquidity Position**: As of September 30, 2025, the company had $298.5 million in working capital, positioning it favorably for project advancement [24].

Core Viewpoint - China Tongfu (01763) has made a significant breakthrough in the stable isotope field by launching carbon isotope products, positioning China among the few countries capable of producing high-abundance CO gas and carbon-13 urea raw materials [1] Company Summary - The launch of high-abundance CO gas, a key raw material for urea breath tests used to detect Helicobacter pylori infections, marks the end of China's complete reliance on imports for this material [1] - China Tongfu has enhanced its research and production capabilities in stable isotope products, establishing itself as a leading enterprise with a complete grasp of the entire industrial chain for breath test products [1] Industry Summary - The initiation of the second phase of the stable isotope base project will enable China Tongfu to ensure a stable supply of high-abundance CO gas, carbon-13 urea raw materials, and other raw materials for gastrointestinal disease treatment [1] - This development is expected to significantly contribute to improving national health standards, promoting high-quality development of medical isotopes, and supporting the "Healthy China" initiative [1]

Core Viewpoint - China Tongru (01763.HK) has announced the launch of carbon isotope products, marking a significant breakthrough in high-end technology in the stable isotope field, making China one of the few countries capable of producing high-abundance 13CO gas and carbon-13 urea raw materials for pharmaceuticals [1] Group 1: Product Launch and Significance - The release of high-abundance 13CO gas is crucial for the urea breath test used to detect Helicobacter pylori infection, indicating a shift from complete reliance on imports for this material [1] - This product launch significantly enhances China's research and production capabilities in stable isotope products, positioning China Tongru as a leading enterprise with a complete grasp of the entire industrial chain for breath test products [1] Group 2: Future Developments - On the same day, China Tongru officially commenced the construction of the second phase of its stable isotope base project, which will establish a stable supply capability for high-abundance 13CO gas, carbon-13 urea raw materials, and other raw materials for gastrointestinal disease treatment drugs [1] - The completion of this project is expected to contribute to improving national health levels, promoting high-quality development of medical isotopes, and supporting the "Healthy China" initiative [1]

Investment Rating - The report recommends a "Buy" rating for the industry, predicting that the industry index will outperform the Shanghai Composite Index by 10% or more during the specified period [6]. Core Insights - The company produced 180,000 pounds of U3O8 in Q2 2025 and expects a total production of approximately 1 million pounds of finished U3O8 for the year [1][9]. - The average uranium grade at the Pinyon Plain mine is reported to be 2.23%, making it one of the highest-grade uranium mines in U.S. history [1]. - The company anticipates a decrease in production costs starting from Q4 2025, with expected sales costs dropping to between $30 and $40 per pound by Q1 2026 [7][8]. Production and Sales - In Q2 2025, the company sold 50,000 pounds of U3O8 at an average price of $77.00 per pound, generating total revenue of $3.85 million with a gross margin of 31% [2]. - The company holds a total inventory of 1.875 million pounds of U3O8 as of June 30, 2025, which includes 725,000 pounds of finished U3O8 [4][10]. - The company has adjusted its sales guidance for 2025 from 220,000 pounds to 350,000 pounds of U3O8, reflecting increased demand from utility customers [12]. Cost Structure - The weighted average cost of finished U3O8 inventory as of June 30, 2025, is approximately $53.00 per pound [8]. - The company expects to achieve a total weighted average sales cost of $23 to $30 per pound of U3O8, positioning it among the lowest production costs globally [7]. Project Development - The company is actively developing its Pinyon Plain mine and has reported excellent drilling results, indicating the potential for increased uranium resources [13]. - The Donald rare earth project in Australia has received final regulatory approval, with a final investment decision expected by Q4 2025 [16]. Financial Performance - In Q2 2025, the company reported total revenues of $4.212 million, a decrease of 52% year-over-year and a 75% decrease quarter-over-quarter [23]. - The net loss for Q2 2025 was $21.812 million, with total operating funds of $253.23 million, including $71.49 million in cash and cash equivalents [24].